Trailblazer (I5t-Mc-Aaci): Assessment Of Safety, Tolerability, And Efficacy Of Donanemab In Early Symptomatic Alzheimer’S Disease
Posted Date: Jun 9, 2020
- Investigator: Lawrence Goldstick
- Type of Study: Drug
To assess the effect of donanemab versus placebo on clinical progression in participants with early symptomatic AD with demonstrated presence of tau pathology
Criteria:
Patients Must Be Between The Ages Of 60-85 Years Of Age Who Have A Gradual Change In Memory For At Least 6 Months.
Keywords:
Alzheimers Disease, Dementia, Donanemab
For More Information:
Sarah Ross
9375355013
hitism@ucmail.uc.edu